NCT03028519View on ClinicalTrials.gov

Vitamin D, Leptin, Vitamin D Receptor Polymorphism, and Treatment-Related Morbidity in Ovarian Cancer

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

81

Participants

Timeline

Start Date

January 31, 2017

Primary Completion Date

December 30, 2020

Study Completion Date

December 30, 2020

Conditions
Ovarian Cancer
Interventions
DRUG

Vitamin D3

Vitamin D3

Trial Locations (1)

73104

University of Oklahoma Health Sciences Center, Oklahoma City

All Listed Sponsors
lead

University of Oklahoma

OTHER

NCT03028519 - Vitamin D, Leptin, Vitamin D Receptor Polymorphism, and Treatment-Related Morbidity in Ovarian Cancer | Biotech Hunter | Biotech Hunter